Review Note

Last Update: 11/07/2024 02:04 PM

Current Deck: Pharmacology I::Respiratory-Asthma&COPD Drugs

Published

Currently Published Content

Pharmacologic Classification

Class: Anti-inflammatory (Phosphodiesterase-4 Inhibitor)
Drug Name: Roflumilast

Drug Name (generic) LEAVE BLANK

Indications

Severe COPD w/ chronic bronchitis and hx of frequent exacerbations. Not approved to treat asthma (Oral)
Treatment of plaque psoriasis and mild-moderate atopic dermatitis in age 6+ patients (Topical)

MOA + Route

Inhibition of PDE4 leading to accumulation of cAMP to reduce inflammation by suppressing cytokine release & decreasing pulmonary infiltration by neutrophils and other WBCs. ↓ in cough and excess mucus production and improved mucociliary clearance.
Route: PO and Topical

Adverse Effects

Reduced appetite, weight loss, headache, back pain, insomnia

Nursing Considerations

Monitor respiratory status periodically. Monitor for changes in weight, changes in mental status.

Patient Education

Mneumonic

Contraindications

Clinical_uses

Side_effects

Drug_interactions

List

Pharmacokinetics_administration

Pharmacokinetics_bioavailability

Pharmacokinetics_distribution

Pharmacokinetics_half_life

Pharmacokinetics_metabolism

Dosage

Image_pharmacodynamics

Image_clinical_uses

Image_pharmacokinetics

Commercial_name_01

Image_comm_name_01

Commercial_name_02

Image_comm_name_02

Commercial_name_03

Image_comm_name_03

Commercial_name_04

Image_comm_name_04

Commercial_name_05

Image_comm_name_05

Commercial_name_06

Image_comm_name_06

Commercial_name_07

Image_comm_name_07

Commercial_name_08

Image_comm_name_08

Commercial_name_09

Image_comm_name_09

Commercial_name_10

Image_comm_name_10

Extra_MAIN_01

Extra_01

Extra_MAIN_02

Extra_02

Extra_MAIN_03

Extra_03

Extra_MAIN_04

Extra_04

Extra_MAIN_05

Extra_05

Finder

Source

Current Tags:

Pharmacology::Respiratory::Antiinflammatories::Phosphodiesterase-4Inhibitor

Pending Suggestions

No pending suggestions for this note.